HOME >> MEDICINE >> NEWS
Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer

CHICAGO, June 2, 2007 -- ALIMTA (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer , according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a Phase III study suggest that a first-line ALIMTA-based regimen may deliver less toxicity than a commonly used therapy in advanced non-small cell lung cancer (NSCLC). ALIMTA is manufactured and marketed by Eli Lilly and Company.

A prospective, randomized, multicenter Phase III study was conducted to compare ALIMTA plus carboplatin with the commonly used regimen of GEMZAR (gemcitabine HC1 for injection) plus carboplatin (ASCO Abstract # 7517 ). The study, conducted by the Norwegian Lung Cancer Group, enrolled 446 chemonave patients with either stage IIIB or IV NSCLC. The primary purpose of the study was to evaluate if the ALIMTA-carboplatin combination provided increased quality-of-life benefits while offering comparable survival data. As such, the primary endpoint was quality of life (defined in the study as nausea/vomiting; dyspnea or a difficulty in breathing, and; fatigue) and the secondary endpoint was overall survival.

Thus far, 384 patients have been analyzed for toxicity and there were fewer patients in the ALIMTA arm who experienced Grade 3/4 thrombocytopenia or a low platelet level (48 vs. 107, p<.001); leukopenia or a lowering of leukocyte white blood cells (44 vs. 89, p<.001), and; granulocytopenia or a lowering of granulocyte white blood cells (78 vs. 98, p=.02). More patients in the GEMZAR arm received transfusion of platelets (5 vs. 19, p=.02). At this point, no difference in survival has been observed.

The patients in this study received a comparable quality-of-life benefit whether they received ALIMTA and carboplatin or GEMZAR and carboplatin, said Bjrn Henning Grnberg, M.D. of St. Olavs University Hospital in Norway and the studys principal investigat
'"/>

Contact: Neil Hochman
n.hochman@cprworldwideusa.com
212-453-2067
CPR Worldwide
2-Jun-2007


Page: 1 2 3

Related medicine news :

1. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
2. Clinical review -- A psychological approach to the management of irritable bowel syndrome
3. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
4. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
5. Clinical guidelines for blood conservation during cardiac procedures developed
6. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
7. Clinical trial coordinators need more financial conflict-of-interest training
8. Clinical studies evaluate potential treatments for mouth ulcers
9. NIH names Clinical Trial Units for the Microbicide Trials Network
10. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
11. Study in recent issue of Clinical Pediatrics helps pediatricians to understand discipline practices

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/18/2018)... ... October 18, 2018 , ... ... demonstrating the company’s automated preclinical image data analysis tool, InVivoAX™, for quantitative ... finds applications in preclinical imaging of small animal models of human disease. ...
(Date:10/17/2018)... ... , ... The Myers’ have been doing this for five years. This year’s event ... CA 91326. , “The Harvest Festival is another way we like to give back ... Children’s Hospital LA,” said Kris and Keith. , The event includes a 50/50 raffle, ...
(Date:10/16/2018)... ... October 16, 2018 , ... Bastyr University is pleased announce ... Health and Medicine’s (AIHM) Visionary Award for his passionate efforts in forging a ... selected as AIHM’s recipient of the Visionary Award due to his tireless effort ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... ... First Healthcare Compliance, an attorney experienced in employment law, writes frequently on employment ... publications. Recently, she authored a chapter in the Health Care Compliance Professional's Manual ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... and clinical research networking-technology company founded by patient-survivors, and The Avoca Group, ... in the clinical trial execution process, today announced its mutual collaboration that ...
Breaking Medicine News(10 mins):
(Date:10/16/2018)... ... October 16, 2018 , ... Founders of two of ... of algae-based omega-3 products, Ben Kelly of Algarithm Ingredients and Philip Bromley of ... on October 15. The title of their presentation was “Making Algal Omega-3’s Great ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... ... training standards to an international multidisciplinary group of healthcare treatment providers who treat ... courses needed for certification in a live, two-day, 12-hour track at Symposium 2019. ...
(Date:10/13/2018)... ... October 13, 2018 , ... As news hits that the ... over the next five years, from $3200 million in 2017 to $7170 million in ... even help drive this growth further. This news comes hot on the heels of ...
Breaking Medicine Technology:
Cached News: